September 9th, 2014

Podcast 174: PARADIGM and Heart Failure

The PARADIGM-HF trial of LCZ696 — a novel compound that both blocks the renin-angiotensin system with an ARB component and blocks neprilysin’s degradation of natriuretic peptides — increased survival in heart failure by some 20% relative to enalapril. It seems to be a big deal, and the trial’s two principal authors have agreed to talk about their work and its larger meaning.

Running time: 15 minutes

Other links:

The study in the New England Journal of Medicine (free)

NEJM Journal Watch coverage of the study (free)

Comments are closed.

Clinical Conversations

About the Podcast

Comments, suggestions, and story ideas welcome. Learn more about Clinical Conversations.

Follow us:
Follow on Apple Podcasts

Follow on Google Podcasts